Open AccessClinical evaluation of mezlocillin
Author(s) -
Haragopal Thadepalli,
Bhavani Rao
Publication year - 1979
Publication title -
antimicrobial agents and chemotherapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.07
H-Index - 259
eISSN - 1070-6283
pISSN - 0066-4804
DOI - 10.1128/aac.16.5.605
Subject(s) - mezlocillin , medicine , thrombophlebitis , adverse effect , surgery , osteomyelitis , antibiotics , anaerobic exercise , abscess , urinary system , thrombosis , pseudomonas aeruginosa , microbiology and biotechnology , physiology , genetics , bacteria , biology , piperacillin
The safety and efficacy of intravenous mezlocillin were determined in 25 patients with aerobic, anaerobic, and mixed infections. Included were pleuropulmonary, urinary tract, skin, and soft-tissue infections, osteomyelitis, and abdominal and breast abscess. Nineteen patients (76%) were cured without recurrence as determined by clinical and bacteriological parameters. In three, the infection recurred (12%); two patients failed (8%), and in one, it was indeterminate (4%). No serious adverse effects were noted except for severe thrombophlebitis in three (12%) patients. Our preliminary data suggest that mezlocillin is a safe (except for thrombophlebitis) and effective antibiotic in the treatment of aerobic anaerobic, and mixed infections.